Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

Everyday our BIO Official Bloggers, writers who are on top of the biotechnology beat, release statements about their experience at the BIO International Convention. Here is what they want to share with you today:

Scrip Intelligence
By Lisa LaMotta

Roche’s strong deal-making position is at least partly due to its acquisition of Genentech, but partnering head Sophie Kornowski-Bonnet explained that the firm is more interested in looking for drugs than bolt-on companies. Read more…

 

Genomics Blog
By Mike Spear

The number of women you’ll see on the Boards of biotech companies, heading up research labs, or making up conference agendas is not representative of the numbers of women who are actually a part of the biotech sector. Over half of biotech companies in Europe and the US have all-male Boards and an analysis of speakers at major biotech and healthcare conferences shows that less than 10% of the speakers are women. (Liftstream, Diversifying the Outlook: the X&Y of Biotechnology Leadership, 2014)
Read more…

Randy Yatscoff is on the Board of Directors for BioAlberta and is also Executive Vice President, Business Development with Tec Edmonton. He wore both hats when he joined me in the BIOBuzz area at BIO in Philadelphia so we could talk about what can be done to promote the profile and the value of Alberta biotechnology industry. Read More…

There is a certain image we tend to have for a biotech company. Usually the picture includes the latest high tech, hustling sales people, a large scientific team, and a big marketing plan. Alan Danroth and Glenn Weagle of General Intermediates Canada based in Edmonton don’t quite fit into that picture. Read more…

 

Research!America

Brokaw, who was diagnosed with multiple myeloma two years ago, said he was fortunate to receive quality health care, but many Americans do not have the same options.

“We need big ideas” in politics and “a big debate” on health care and innovation, he added. “Healthcare is the underpinning of who we are. It governs every part of our waking day.” Drug pricing should be part of the debate, he added, to find solutions for increasing access to care. He told the BIO Convention audience that he’s in awe of what has been accomplished in immunotherapy and continues to pay close attention to medical breakthroughs. Read more…

Is the cost of some drugs a barrier? Are we adequately pricing the value of innovation? To ensure breakthroughs continue to reach patients, Scott Gottlieb, resident fellow, American Enterprise Institute, suggested that we need an approach to financing care that’s as modern and as imaginative as the medicines that are being invented.  “The science has advanced enormously but our financial provisions for funding delivery of these drugs haven’t changed for decades,” he said. Policy obstacles are preventing experimentation with how drugs are priced. Read more…

 

Informa’s BIO2015 Blog
By Lisa LaMotta

Chris Guiffre, CEO of Cerulean Pharma, says, “You haven’t heard of me yet,” but he hopes that pairing the cancer drugs his tiny biotech makes with offerings from major pharma companies will change that. Read more…

By Donna Young

Too often, biopharmaceutical firms put their investment and attention mostly on research and development and gaining regulatory approval and fail to provide equal support to the commercial market access side of their businesses – which can ultimately result in a successfully approved drug being a flop in the marketplace, three expert consultants said during a 16 June session at the annual Biotechnology Industry Organization (BIO) International Conference in Philadelphia. Read more…

By Sue Sutter

During a panel discussion entitled “Paying for the 21st Century Cure,” Dan Durham, acting CEO of America’s Health Insurance Plans, and American Enterprise Institute Resident Fellow Dr. Scott Gottlieb made the argument for moving beyond the current product-based approach to granting breakthrough status and, instead, extending the expedited pathway’s benefits to subsequent treatments that target the same indication. Read more…

In early February, biosimilar developer Pfenex Inc. was on the verge of a transformative deal with Hospira Inc. to bring a proposed biosimilar of Genentech Inc.’s ocular VEGF-inhibitor Lucentis (ranibizumab) to market. Then it got some news that caused a bit of gastroesophageal reflux: Pfizer Inc. was acquiring Hospira for $17 billion. Read more…

By John Hodgson

Scrip looked at a day’s worth of #BIO2015 Tweets from the first day of the BIO convention expecting to find some interesting discussion on drug payment, Obamacare, PD1/PDL-1 inhibitors or even some abstruse self-promotion from thought-provoking biotech companies. We thought that assessing the interest in a subject from the number of retweets or “favoriting” would be a good way of assessing what the BIO2015 Twitterati found fascinating. Read more…

 

BiotechBlog

Check out the array of posts on the biotech bulletin. Read more…

 

Bloomberg BNA- Health Care Blog
By John T. Aquino

There’s been a lot of talk about statistics on the inter partes review (IPR) process for challenging patent claims, but an administrative patent law judge offered her own perspective on the statistics at the BIO convention. Read more…

Patent eligibility has been an issue for the life sciences industry since two Supreme Court decisions that panelists Wednesday at a BIO session said have driven the patent system into “chaos.” Read more…

 

Nature.com
By
Michael Francisco

The difference in the patenting landscape between the United States and Europe used to be characterized as freewheeling versus cautionary; expansive versus patchwork. Think of Diamond v. Chakrabarty‘s “anything under the sun that is made by man” versus the long battle to finally allow the patenting of stem cells in Europe. Read more…

 

Filed under: Events, , , , , , , ,